News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015
FREMONT, Calif. , May 19, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically
View HTML
Toggle Summary Ardelyx Reports First Quarter 2015 Financial Results
FREMONT, Calif. , May 12, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced financial results for the first quarter ended March 31, 2015 .
View HTML
Toggle Summary Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria
-- Conference Call and Webcast Today at 5:00 p.m. ET --
View HTML
Toggle Summary Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors
FREMONT, Calif. , April 20, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Annalisa Jenkins , MBBS , MRCP, has joined the Company's Board of Directors. Dr.
View HTML
Toggle Summary Ardelyx to Present at the 22nd Annual Future Leaders in the Biotech Industry Conference
FREMONT, Calif. , March 13, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that Mike Raab , President and Chief Executive Officer, will present a corporate overview at
View HTML
Toggle Summary Ardelyx Reports Fourth Quarter and Full Year 2014 Financial Results
Completed Two Tenapanor Phase 2b Clinical Trials in Patients with Constipation-Predominant Irritable Bowel Syndrome (IBS-C) and in Chronic Kidney Disease Patients with Hyperphosphatemia (CKD-5D)Phase 2a Data for Tenapanor in CKD Patients Expected in 2Q 2015Conference Call and Webcast Today at 4:30 p.m. ET
View HTML
Toggle Summary Ardelyx to Report Fourth Quarter and Full Year 2014 Financial Results on February 25th, 2015
FREMONT, Calif. , Feb. 18, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report its financial results for fourth quarter and full year ended December 31,
View HTML
Toggle Summary Ardelyx to Present at the 2015 Leerink Global Healthcare Conference
FREMONT, Calif. , Feb. 9, 2015 /PRNewswire/ --   Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that Mike Raab , President and Chief Executive Officer and David Rosenbaum Ph.D., Senior Vice
View HTML
Toggle Summary Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
FREMONT, Calif. , Feb. 2, 2015 /PRNewswire/ --   Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that AstraZeneca's 161-patient Phase 2b clinical trial evaluating tenapanor in
View HTML
Toggle Summary Ardelyx Appoints Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer
FREMONT, Calif. , Dec. 1, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced the appointment of Jeremy S. Caldwell , Ph.D., as Executive Vice President and Chief Scientific
View HTML